Hikma Pharmaceuticals HIK.L
Hikma Pharmaceuticals is a pharmaceutical company that develops, manufactures, and markets generic, branded, and injectable medicines in the Middle East, North Africa, and the United States. Hikma Pharmaceuticals trades at a P/E of 12.05 and a forward P/E of 8.52, reflecting an attractive valuation supported by an ROIC of 17.65% and an operating margin of 23.49%, although earnings growth is negative (-4.70%) and momentum is weak (-12.36%).
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Hikma Pharmaceuticals is a pharmaceutical company that develops, manufactures, and markets generic, branded, and injectable medicines in the Middle East, North Africa, and the United States. Hikma Pharmaceuticals trades at a P/E of 12.05 and a forward P/E of 8.52, reflecting an attractive valuation supported by an ROIC of 17.65% and an operating margin of 23.49%, although earnings growth is negative (-4.70%) and momentum is weak (-12.36%).
Score by category
| Category | Score |
|---|---|
| Financial health | 7.3 |
| Quality / Moat | 5.4 |
| Valuation | 6.6 |
| Growth | 4.5 |
| Dividend | 4.8 |
| Momentum | 2.0 |
| Risk & Context | 7.7 |
OVERALL SCORE: 5.8/10
Context and risks
Moderate regulatory risk in the UK and exposure to Middle East and North Africa markets, with geopolitical risk in the region that may affect the supply chain and demand.
News considered in the analysis
- Jefferies lifts Hikma target as CMO deal underpins growth story — El acuerdo CMO (fabricación por contrato) refuerza la narrativa de crecimiento y el objetivo de precio elevado por Jefferies es una señal positiva moderada.
- Citi sees Hikma discount as unwarranted after upgrade to forecasts — Citi considera que el descuento de valoración no está justificado tras mejorar sus previsiones, lo que apoya la tesis de infravaloración.
- Hikma boost as broker raises price target — La subida del precio objetivo por parte de un bróker es un catalizador positivo moderado que refuerza la confianza en el valor.
- Health Care Roundup: Market Talk — Listículo sin información específica sobre Hikma.
- Hikma Pharmaceuticals (LSE:HIK) Stock Fair Value Edges Higher After Bullish Analyst Targets — Artículo genérico que resume objetivos de analistas ya conocidos, sin información nueva.
Verdict: Hold, with potential accumulation on dips, given the valuation discount and analyst forecast upgrades, but monitoring the evolution of earnings growth.
Main risk: The main risk is geopolitical exposure to the Middle East and North Africa, which could affect the supply chain and demand, along with weak earnings growth (-4.70%) that may persist.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →